239 related articles for article (PubMed ID: 34575565)
1. Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Yoon DY; Lee S; Jang IJ; Kim M; Lee H; Kim S; Kim B; Song GS; Rhee SJ
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575565
[TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators.
Ngo LT; Lee J; Yun HY; Chae JW
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678810
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the Drug-Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model.
Wei Z; Jeong HC; Kim MG; Shin KH
Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986460
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
7. Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations.
Jeong HC; Kim MG; Wei Z; Lee KR; Lee J; Song IS; Shin KH
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745870
[TBL] [Abstract][Full Text] [Related]
8. Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.
Jia G; Ren C; Wang H; Fan C
BMC Pharmacol Toxicol; 2024 Jan; 25(1):4. PubMed ID: 38167223
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.
Li T; Zhou S; Wang L; Zhao T; Wang J; Shao F
J Pharmacokinet Pharmacodyn; 2024 Mar; ():. PubMed ID: 38554227
[TBL] [Abstract][Full Text] [Related]
10. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Jing J; Chen Y; Musib L; Jin JY; Cheung KWK; Yoshida K; Sane R
Cancer Chemother Pharmacol; 2022 May; 89(5):707-720. PubMed ID: 35428895
[TBL] [Abstract][Full Text] [Related]
13. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chiney MS; Ng J; Gibbs JP; Shebley M
Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
[TBL] [Abstract][Full Text] [Related]
15. A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators.
Marok FZ; Wojtyniak JG; Fuhr LM; Selzer D; Schwab M; Weiss J; Haefeli WE; Lehr T
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840001
[TBL] [Abstract][Full Text] [Related]
16. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
17. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
